Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Exelixis ( (EXEL) ) has provided an announcement.
On May 28, 2025, Exelixis held its Annual Meeting via live webcast, where stockholders elected 11 directors to serve until the next annual meeting in 2026. Additionally, stockholders ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending January 2, 2026, and approved the executive compensation proposal.
The most recent analyst rating on (EXEL) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Exelixis stock, see the EXEL Stock Forecast page.
Spark’s Take on EXEL Stock
According to Spark, TipRanks’ AI Analyst, EXEL is a Outperform.
Exelixis receives a strong score driven by excellent financial performance, positive earnings call outcomes, and favorable technical indicators. While the valuation is reasonable, the absence of a dividend yield and operational expense challenges slightly temper the overall outlook. The strategic focus on pipeline development and a robust cash position further bolster confidence in its growth trajectory.
To see Spark’s full report on EXEL stock, click here.
More about Exelixis
Exelixis operates in the biotechnology industry, focusing on the development and commercialization of new medicines to treat cancer.
Average Trading Volume: 3,015,183
Technical Sentiment Signal: Buy
Current Market Cap: $11.74B
Find detailed analytics on EXEL stock on TipRanks’ Stock Analysis page.